Aurobindo Pharma’s Subsidiary Receives ‘Official Action Indicated’ Classification from US FDA
Aurobindo Pharma Limited announced on March 17, 2026, that the United States Food and Drug Administration (US FDA) has classified Unit-II of Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma, as ‘Official Action Indicated’ (OAI).Eugia Pharma Specialities Limited’s Unit-II, located in the RIICO Industrial Area, Phase -III, Bhiwadi, Rajasthan, was inspected by the US FDA from November 3 to November 14, 2025. Following the inspection, a ‘Form 483’ was issued, detailing nine observations.Aurobindo Pharma stated that it currently does not anticipate any impact on business operations as a result of this...